This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
By This Author:
Page 2 of 65

JNPR Preview: Big Beat Unlikely ( $)

By Ken Shreve

The revenue number and outlook are what investors will be most concerned with.

04:17PM 07/25/11

Gulfport's a Compelling Small-Cap ( $)

By Ken Shreve

The stock is being accumulated as a solid base takes shape. A breakout could be in the works.

11:15AM 07/22/11

FFIV Summary: Decent Isn't Good Enough ( $)

By Ken Shreve

Traders are selling the stock after-hours on news of soft sales and in-line guidance.

06:37PM 07/20/11

You're Not Too Late ( $)

By Ken Shreve

A number of stocks are not yet extended, even after Tuesday's big gains.

11:30AM 07/20/11

FFIV Preview: Gearing Up for Growth ( $)

By Ken Shreve

Analysts are looking for earnings of $0.91 a share on sales of $290.7 million.

04:40PM 07/19/11

A Pharma That's Worth a Listen ( $)

By Ken Shreve

Jazz Pharmaceuticals' stock surges on an analyst's note, and sales of its key drug are growing.

10:46AM 07/15/11

Not Sounding the Bear Alarm Yet ( $)

By Ken Shreve

Some yellow flags are signaling caution, but bullish charts still dominate the growth screens.

10:45AM 07/14/11

Casey's Is Firing on All Cylinders ( $)

By Ken Shreve

The convenience store company spurned buyout offers and is focused on growth -- and it's paying off.

10:45AM 07/13/11

Curious Movement Under the Surface ( $)

By Ken Shreve

Despite the broadly positive day, there was a lot of downright crummy price action. But these two stocks are setting up nicely.

10:00AM 07/08/11

Investors in Accord with Acorda ( $)

By Ken Shreve

Recent price and volume trends have been solid.

09:15AM 07/07/11

Page 2 of 65

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV


DOW 18,285.74 +0.34 0.00%
S&P 500 2,130.82 +4.97 0.23%
NASDAQ 5,090.7940 +19.0510 0.38%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs